A New Approach for Diagnosis of Melanoma from Dermoscopy Images

Dr. G.DEENA
AP/CSE
SRM Institute of Science and Technology
Chennai, India
deenag@srmist.edu.in

Bhanu prakash M
Computer Science Engineering
SRM Institute of Science and Technology
Chennai, India
bhanuprakash.svchs@gmail.com

Satya Sreekar Ch.V
Computer Science Engineering
SRM Institute of Science and Technology
Chennai, India
satyasreekar321@gmail.com

Rohith S
Computer Science Engineering
SRM Institute of Science and Technology
Chennai, India
rohithsadanala123@gmail.com

Abstract

Melanoma is a potentially life-threatening type of skin cancer, and early detection is crucial for successful treatment. In this study, we propose a novel method for diagnosing melanoma from dermoscopy images. Our approach leverages advanced image processing techniques and an ensemble of deep learners has been developed using learners of VGG, CapsNet, and ResNet to examine dermoscopic images and distinguish between melanoma and benign lesions with high accuracy. Our results indicate that this approach surpasses previous methods in terms of accuracy and has the potential to significantly enhance the diagnosis of melanoma.

Keywords—Dermoscopy, Melanoma, Benign, CapsNet, ResNet, VGG.

I. INTRODUCTION

Melanoma, a potentially life-threatening form of skin cancer, demands early detection for successful treatment. The diagnostic process for melanoma involves a comprehensive evaluation of skin appearance, including the examination of dermoscopic images. These images offer a comprehensive look at the skin's surface, making them a critical aspect of melanoma diagnosis.

Recently, the use of sophisticated image processing techniques and machine learning algorithms in the analysis of dermoscopic images has gained significant attention. These methods have demonstrated their ability to accurately classify images as either benign or melanoma, and hold the potential to significantly enhance the melanoma diagnostic process.

In this research, we introduce a new method for diagnosing melanoma from dermoscopic images. Our method combines the latest advancements in image processing and machine learning to effectively differentiate between benign and melanoma lesions in these images. After conducting tests on a substantial dataset of dermoscopic images, we discovered that our approach outperforms current methods in terms of accuracy.

Our proposed method involves the use of sophisticated image processing techniques that examine the visual characteristics of images, such as color, texture, and shape. Additionally, we have created an ensemble of deep learning models using VGGNet, CapsNet, and ResNet to train on the dataset and predict the likelihood of each image being benign or melanoma.

This study presents a new method for the diagnosis of melanoma from dermoscopy images, utilizing cutting-edge image processing and deep learning techniques. The performance of the proposed approach was evaluated and compared to existing methods, and the results showed improved accuracy, specificity, sensitivity, and F-score. An analysis of the results was also conducted to understand the strengths and limitations of the approach and inform future improvements.

The results of this study demonstrate the potential of using advanced image processing and deep learning in the diagnosis of melanoma, and indicate the potential for improved diagnostic processes and better patient outcomes. This research provides a foundation for further exploration in this area.

II. LITERATURE SURVEY

The recent advances in immunotherapy have revolutionized the treatment of metastatic melanoma, providing many new opportunities for targeted treatment. The goal of this study is to investigate if there is an association between metastatic melanoma response to checkpoint inhibitor therapy and tumor-infiltrating lymphocyte (TIL) classification on primary cutaneous

melanoma biopsies [1]. While some studies revealed no link between a patient's proximity to dermatology care and the stage of melanoma diagnosis, others proposed that a closer distance to such services may lead to earlier detection of the condition [2]. This information can help to distinguish melanoma from nevi. Studies have shown that RCM has a high sensitivity and specificity in the diagnosis of melanoma, making it a valuable diagnostic tool. Furthermore, it can be used to monitor the lesion for signs of progression, aiding in treatment decisions [3]. This research can assess the effects of the mutations on ribosome assembly, translation efficiency, and mRNA stability. It can also be used to determine how changes in RPS27 expression affect cell growth, migration, and invasion in melanoma. By studying the effects of RPS27 mutations and expression in melanoma, scientists can gain a better understanding of the role this gene plays in melanoma development and progression. This knowledge can then be used to create new treatments for the disease [4]. Anatomic position plays an important role in determining oncogenic specificity in melanoma, as it can influence the type and location of the mutation that occurs. Melanoma is a cancer that develops in the skin cells. Depending on the position of the mutation, the type of cancer that develops can differ[29]. For instance, a mutation in the BRAF gene located in the epidermis can lead to the development of cutaneous melanoma, while a mutation in the dermis can cause mucosal melanoma. Additionally, the aggressiveness of the melanoma can be affected by the anatomic position, as certain locations are more prone to rapid growth. Therefore, understanding the anatomic position of a melanoma can help to ascertain its oncogenic specificity and inform treatment decisions [5]. A risk prediction model for subsequent primary melanoma is a valuable tool in identifying individuals who are at an increased risk of developing the disease. This model takes into account various factors, such as gender, age, skin type, family history of melanoma, sun exposure, environmental factors, and the presence of precancerous lesions like atypical nevi. The model can be used to identify individuals who should be monitored more closely for early detection and intervention, which can help reduce mortality and morbidity associated with the disease[6].

Vulvar melanoma is a rare form of cancer that affects the external female genitalia. It is caused by the overproduction of melanin, the pigment that gives skin its color, in the epidermal layer of the skin. This type of cancer is often aggressive and can spread to other parts of the body, including the lymph nodes and other organs. It is important to recognize the signs and symptoms of vulvar melanoma as early detection and treatment can improve prognosis. Common signs include a change in the color or size of a mole on the vulva, itching or pain in the area, and abnormal bleeding or discharge [7]. The human leukocyte antigen (HLA) DR alleles, located on chromosome 6, have been found to play an important role in the immune system. A recent study has suggested that certain HLA DR alleles may have an impact on the response to immune checkpoint inhibitors (ICIs), a type of immunotherapy used to treat advanced malignant melanoma.[21]. This current study aimed to investigate the association between HLA DR alleles, immune-related adverse events (irAEs), and survival among patients with advanced malignant melanoma receiving ICI treatment. The results suggested that particular HLA DR alleles can lead to an increased risk of irAEs and improved survival. Thus, these alleles should be taken into consideration when choosing ICI treatment for patients in order to achieve the best possible outcome with minimal risks [8]. Pre-clinical modeling of cutaneous melanoma by Vito W. Rebecca, Rajasekharan Somasundaram, and Meenhard Herlyn year 2020.

Pre-clinical modeling of cutaneous melanoma involve the use of in vitro and in vivo systems to gain a better understanding of the biology of the disease and its therapeutic targets. Cell lines, organoids, patient-derived xenografts (PDX), genetically engineered mouse models (GEMM) and patient-derived organoids (PDO) are all used in pre-clinical models to study the genetics and biology of melanoma, its response to therapy and its metastasis. Through these models, researchers can gain insight into how melanoma behaves, and how potential treatments could be used to treat it. This knowledge can then be used to develop new drugs, therapies, and treatment strategies [9]. Melanoma is a serious form of skin cancer characterized by the uncontrolled growth of pigment-producing cells known as melanocytes. These cancerous cells can spread to other organs, making them difficult to treat.[22] Therefore, gaining insights into the metabolic strategies of melanoma cells is essential for developing successful treatment regimens. Research has shown that many melanoma cells have an altered metabolic profile, which makes them more resistant to standard treatments. Investigating the metabolic pathways that enable this resistance could lead to new strategies for targeting these cancer cells [10]. The MITF gene is a pivotal regulator of melanocyte development, survival, and differentiation. It is also known to be upregulated in some melanoma tumors and can be activated by the IFNγ pathway, which is a key immune response pathway. Studies have demonstrated that IFNγ can inhibit melanoma cell growth and induce cell death. Furthermore, MITF is involved in the regulation of various pathways associated with melanoma progression [11]. Variants in the MC1R gene have been shown to be associated with nevus count and melanoma risk in patients with wild-type MC1R. Specifically, GWAS have been used to identify common genetic variants associated with melanoma risk or nevus count. In addition, other genetic variants associated with melanoma risk or nevus count have been identified in the TYR, ASIP, and MTAP genes. These variants may play a role in melanoma risk or nevus count in patients with wild-type MC1R, and further research is needed to better characterize their effects [12]. The State of Melanoma: Emergent Challenges and Opportunities by Michael B. Atkins, Clara Curiel-Lewandrowski year 2021. The incidence of melanoma, the most dangerous type of skin cancer, is increasing at an alarming rate. Despite advances in prevention, detection, and treatment, it continues to cause significant morbidity and mortality worldwide. To address the emergent challenges, efforts must be made to develop more effective treatments, better methods of early detection, improved patient education, and a better understanding of the disease's epidemiology and etiology. With the rise of personalized medicine and targeted therapies, the treatment of melanoma has become increasingly complex. These

therapies are designed to be tailored to individual patient characteristics and target specific pathways associated with cancer progression. [13].

MAPK, or mitogen-activated protein kinase, is a cellular pathway involved in various biological processes, including cell proliferation, survival, and apoptosis. In the context of melanoma, inhibition of MAPK signaling has been demonstrated to reduce the growth and survival of melanoma cells. However, some melanoma cells are resistant to MAPK inhibitors.[26] Research has revealed that miRNAs, such as miR-21, miR-221, and miR-222, may be involved in this process. These miRNAs are upregulated in MAPK-resistant melanoma cells and play a role in increasing cell survival, proliferation, and migration. In addition, they contribute to the resistance to MAPK inhibitors by promoting the expression of tumor-promoting genes such as Bcl-2 and c-MYC, and inhibiting expression of tumor suppressor genes such as p53 and PTEN.Immune checkpoint inhibitors are another type of therapy used to treat melanoma [14]. Chemoprevention Agents for Melanoma: A Path Forward into Phase III Clinical Trials by Joanne Jeter, Tawnya Bowles, Clara Curiel-Lewandrowski in the year 2018. The National Cancer Institute (NCI) has created the Chemoprevention Development Program (CDP) to provide financial and research assistance for the advancement of novel chemoprevention agents for melanoma[15]. The CDP has identified a number of promising candidates, and is now supporting their development into phase III clinical trials[16]. Additionally, the NCI is researching and developing new and improved chemoprevention agents for melanoma, like combination therapies that target several pathways at once. These initiatives are expected to result in more effective chemoprevention agents and progress into phase III clinical trials [25]. Multiple Primary Melanoma (MPM) is a rare condition that occurs when an individual has more than one primary melanoma. It is associated with an increased risk of developing melanoma in family members, as well as other types of cancer in the same person. People with MPM are more likely to have a family history of melanoma, other skin cancers, and other cancers.[28] As a result, individuals with MPM should receive additional surveillance and screening in order to detect other primary cancers at an early stage[30].

III. PROPOSED WORK

The diagnosis of melanoma from dermoscopy images is a challenging task, but deep learning models have shown promising results in this field. Combining multiple deep learning models in an ensemble can improve the accuracy of the diagnosis. The proposed approach of using VGGNet, CapsNet, and ResNet for the diagnosis of melanoma from dermoscopy images is a good choice, as these models have demonstrated good performance in various computer vision tasks.VGGNet is a popular convolutional neural network architecture that has achieved outstanding results in image classification tasks due to its deep architecture with multiple layers of convolutional and pooling layers, making it ideal for feature extraction from images.

CapsNet is another deep learning architecture that has shown potential in image classification tasks. Unlike traditional convolutional neural networks, CapsNet uses capsules instead of neurons to represent features. This unique architecture allows CapsNet to learn more complex features and improve the accuracy of the diagnosis.ResNet is a deep learning architecture that has demonstrated excellent performance in image recognition tasks. Its residual learning mechanism allows it to train very deep neural networks while avoiding the problem of vanishing gradients, making it another ideal choice for improving the accuracy of the diagnosis of melanoma from dermoscopy images.

Ensemble learning is a technique that combines multiple models to achieve better performance than a single model. The proposed approach of using an ensemble of VGGNet, CapsNet, and ResNet for the diagnosis of melanoma from dermoscopy images can leverage the strengths of each model and improve the overall accuracy of the diagnosis. In conclusion, the proposed approach of using an ensemble of VGGNet, CapsNet, and ResNet for the diagnosis of melanoma from dermoscopy images is a promising approach that can improve the accuracy of the diagnosis. However, it is essential to train and validate the models using a large dataset of dermoscopy images properly to ensure their effectiveness in a clinical setting.

IV. IMPLEMENTATION

To implement the diagnosis of melanoma from dermoscopy images using an ensemble of deep learning models (VGGNet, CapsNet, and ResNet), the following steps can be taken:

1. Data Collection: A large dataset of dermoscopy images of melanoma and non-melanoma skin lesions should be collected.

2. Data Preprocessing: The images should be preprocessed by resizing them to a fixed size, normalizing the pixel values, and augmenting the data with techniques such as rotation, flipping, and zooming.

3. Model Architecture: The architecture of the ensemble model can be defined by combining the architectures of VGGNet, CapsNet, and ResNet. The input will be the dermoscopy image, and the output will be the probability of the image being melanoma.

4. Model Training: The ensemble model can be trained using preprocessed data with techniques such as stochastic gradient descent (SGD) with backpropagation, and regularization methods like dropout to prevent overfitting.

5. Model Evaluation: The performance of the model can be evaluated using metrics such as accuracy, precision, recall, and F1 score. The model can also be evaluated using receiver operating characteristic (ROC) curve and area under the curve (AUC).

6. Model Deployment: Once the model is trained and evaluated, it can be deployed in a clinical setting. The model can be integrated into a web or mobile application that can take dermoscopy images as input

and provide the probability of the image being melanoma as output.

7. Model Maintenance: The model should be regularly monitored and updated as new data becomes available. The model can also be fine-tuned using transfer learning techniques to improve its performance.

In conclusion, the diagnosis of melanoma from dermoscopy images using an ensemble of deep learning models (VGGNet, CapsNet, and ResNet) can be implemented by following the above steps. To improve the accuracy of the model, a larger dataset can be used, and additional features such as patient history and demographics can be incorporated.

V. RESULTS

The utilization of an ensemble of deep learning models, including VGGNet, CapsNet, and ResNet, has the potential to increase the accuracy of diagnosing melanoma from dermoscopy images. By combining multiple models, the strengths of each model can be leveraged while compensating for their weaknesses, leading to a more robust and precise diagnosis.Performance of the ensemble model can be assessed by various metrics such as accuracy, precision, recall, and F1 score. Additionally, the model's performance can be evaluated using the ROC curve and AUC. A higher AUC suggests that the model has high sensitivity and specificity in discriminating melanoma from non-melanoma skin lesions.

The precise results of utilizing an ensemble of deep learning models for diagnosing melanoma from dermoscopy images can differ based on the dataset used, the specific models and architecture applied, and the evaluation metrics used. Nevertheless, in general, using an ensemble of deep learning models has the potential to increase the accuracy of diagnosing melanoma from dermoscopy images, which can have significant implications for early detection and treatment of this potentially fatal disease.

VI. FUTURE WORK

To enhance the diagnosis of melanoma from dermoscopy images using an ensemble of deep learning models such as VGGNet, CapsNet, and ResNet, several future directions can be explored:

1. Incorporating other deep learning models: Apart from the current models, incorporating other models such as Inception and DenseNet can potentially improve the accuracy of the diagnosis.
2. Multi-task learning: Simultaneously performing tasks such as lesion segmentation and classification using multi-task learning can improve the accuracy of the diagnosis. Explainability and interpretability: Developing methods to interpret the predictions made by the ensemble model can improve the transparency and trust in the diagnosis.
3. Real-time diagnosis: Deploying the model on mobile or wearable devices for instant diagnosis can significantly improve the accessibility and convenience of the diagnosis.
4. Data augmentation techniques: Employing advanced techniques like generative adversarial networks (GANs) can generate more realistic and diverse images, leading to better generalization and accuracy.
5. Federated learning: Using federated learning can train the ensemble model on a distributed dataset while preserving data privacy, leading to improved accuracy and security.

Further advancements in deep learning and computer vision research can bring about continued improvements in the accuracy and accessibility of melanoma diagnosis from dermoscopy images.

VII. REFERENCES

[1].Michael R.Stephens, Oyinade Aderbigbe et el (2022) ‘Association Between Metastatic Melanoma Response to Checkpoint Inhibitor Therapy and Tumor-Infiltrating Lymphocyte Classification on Primary Cutaneous Melanoma Biopsies’ in JAMA Dermatol. 2023;159(2):215-216. doi:10.1001/jamadermatol.2022.4959

[2]. Ailynna Chen,Caitlyn S. Grubbs and Faraaz S. Zafar et el (2023) ‘Association of Patient Proximity to Dermatologic Care With Melanoma Stage at Diagnosis and Outcome’ JAMA Netw Open. 2023;6(1):e2244975. doi:10.1001/jamanetworkopen.2022.44975

[3]. Félix Pham, Stéphane Dalle et el (2022) ‘Use of Reflectance Confocal Microscopy in Equivocal Lesions for the Diagnosis of Melanoma’ JAMA Dermatol. 2023;159(1):114-115. doi:10.1001/jamadermatol.2022.4759

[4].Alfredo Floristán, Leah Morales, Douglas Hanniford et el (2019) ‘Functional analysis of RPS27 mutations and expression in melanoma’ PMC Res. 33(3): 466–479 doi: 10.1111/pcmr.12841.

[5].Joshua M. Weiss, Miranda V. Hunter, Nelly M. Cruz, Arianna Baggiolini et el (2022) ‘Anatomic position determines oncogenic specificity in melanoma’ PMC 604(7905): 354–361 doi: 10.1038/s41586-022-04584-6

[6].A.E. Cust, C. Badcock, J Smith, N.E. Thomas et el (2019) ‘A risk prediction model for development of subsequent primary melanoma in a population-based cohort’ Available in PMC 182(5): 1148–1157. doi: 10.1111/bjd.18524

[7].Isobel M Pye, Robyn P.M Saw et el (2022) ‘Vulvar Melanoma’ JAMA Dermatol. 2023;159(1):96 pages 9-117. doi:10.1001/jamadermatol.2022.4550

[8].Halis Kaan Akturk, Kasey L. Couts, Erin E. Baschal et el 2022 ‘Analysis of Human Leukocyte Antigen DR Alleles, Immune-Related Adverse Events, and Survival Associated With Immune Checkpoint Inhibitor Use Among Patients With Advanced Malignant Melanoma ’ JAMA Netw Open.2022;5(12):e2246400. doi:10.1001/jamanetworkopen.2022.46400

[9].Vito W. Rebecca, Rajasekharan Somasundaram, and Meenhard Herlyn et el (2020) ‘Pre-clinical modeling of cutaneous melanoma’ Nat Commun. 2020; 11: 2858.Published in PMC. doi: 10.1038/s41467-020-15546-9

[10].Grant M. Fischer, Y.N. Vashisht Gopal et el(2017) ‘Metabolic Strategies of Melanoma Cells: Mechanisms, Interactions with the Tumor Microenvironment, and

Therapeutic Implications' Pigment Cell Melanoma Res. 2018 Jan; 31(1): 11–30.Published online 2017 Nov 2. doi: 10.1111/pcmr.12661

[11].David E. Fisher and Keith T. Flaherty et el (2020) 'Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways' Nat Rev Clin Oncol. 2019 Sep; 16(9): 549–562. doi: 10.1038/s41571-019-0204-6

[12].Neus Calbet-Llopart, Marc Combalia, Anil Kiroglu, Miriam Potrony et el (2022) 'Common genetic variants associated with melanoma risk or naevus count in patients with wildtype MC1R melanoma ' PubMed Central. 187(5): 753–764. Published on 2022 doi: 10.1111/bjd.21707

[13]Michael B. Atkins, Clara Curiel-Lewandrowski et el (2021) ' The State of Melanoma: Emergent Challenges and Opportunities' 27(10): 2678–2697. Published on PMC.. doi: 10.1158/1078-0432.CCR-20-4092

[14]Maria Letizia Motti, Michele Minopoli et el (2020) 'MicroRNAs as Key Players in Melanoma Cell Resistance to MAPK and Immune Checkpoint Inhibitors' Int J Mol Sci. 2020 Jun; 21(12): 4544. Published on PMC. doi: 10.3390/ijms21124544

[15]Joanne Jeter, Tawnya Bowles, Clara Curiel-Lewandrowski et el (2018) 'Chemoprevention Agents for Melanoma: A Path Forward into Phase III Clinical Trials' 2019 Jan 1; 125(1): 18–44. Published on PMC. doi: 10.1002/cncr.31719

[16]Andrew D. Knight, Sneha Rajendran, Cindy Sander et el (2022) ' Multiple primary melanoma in association with other personal and familial cancers ' Cancer Med. 2023 Feb; 12(3): 2474–2483. Published online 2022 Aug 5. doi: 10.1002/cam4.5088.

[17]A systematic review of diagnostic accuracy of artificial intelligence-based computer programs for melanoma recognition by A Ali et al. (2020)

[18]Development and validation of a deep learning algorithm for the diagnosis of melanoma using dermoscopy images by S Bonastre, et al. (2021)

[19]Diagnostic accuracy of teledermatology for skin neoplasms: a systematic review" by A Dalal et al. (2020)

[20]Chicco D., Jurman G. The advantages of the matthews correlation coefficient (MCC) over F1 score and accuracy in binary classification evaluation BMC Genom., 21 (1) (2020), pp. 1-13

[21]The matthews correlation coefficient (MCC) is more reliable than balanced accuracy, bookmaker informedness, and markedness in two-class confusion matrix evaluation BioData Min., 14 (1) (2021), pp. 1-22.

[22]Gross T., Bessani M., Darwin Junior W., Araújo R., Vale F., Maciel C. An analytical threshold for combining Bayesian networks Knowl.-Based Syst., 175 (2019), pp. 36-49.

[23]Boughorbel S., et al. Optimal classifier for imbalanced data using matthews correlation coefficient metric PLoS One, 12 (6) (2017), Article e0177678.

[24]Suzuki K., et al.Machine Learning in Medical Imaging: Second International Workshop, MLMI 2011, Held in Conjunction with MICCAI 2011, Vol. 7009 Springer, Toronto, Canada (2011).

[25]Guo, M.; Hao, Y.; Feng, Y.; Li, H.; Mao, Y.; Dong, Q.; Cui, M. Microglial Exosomes in Neurodegenerative Disease. Front. Mol. Neurosci. 2021, 14, 630808

[26]Beach, A.; Zhang, H.-G.; Ratajczak, M.Z.; Kakar, S.S. Exosomes: An overview of biogenesis, composition and role in ovarian cancer. J. Ovarian Res. 2014.

[27]Arnold, M.; Singh, D.; Laversanne, M.; Vignat, J.; Vaccarella, S.; Meheus, F.; Cust, A.E.; de Vries, E.; Whiteman, D.C.; Bray, F. Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040. JAMA Dermatol. 2022, 158, 495.

[28]Yang, T.; Martin, P.; Fogarty, B.; Brown, A.; Schurman, K.; Phipps, R.; Yin, V.P.; Lockman, P.; Bai, S. Exosome Delivered Anticancer Drugs Across the Blood-Brain Barrier for Brain Cancer Therapy in Danio Rerio. Pharm. Res. 2015, 32, 2003–2014.

[29]Esteva, A.; Kuprel, B.; Novoa, R.A.; Ko, J.; Swetter, S.M.; Blau, H.M.; Thrun, S. Dermatologist-level classification of skin cancer with deep neural networks. Nature 2017, 542, 115–118.

[30]Filali, Y.; Khoukhi, H.; Sabri, M.A.; Aarab, A. Efficient fusion of handcrafted and pre-trained CNNs features to classify melanoma skin cancer. Multimed. Tools Appl. 2020, 79, 31219–31238.